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Abstract 
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder caused by loss 
of nigrostriatal dopaminergic pathways.  
PD is generally characterized by bradykinesia, resting tremor, rigidity and postural instability 
and the clinical diagnosis is based on these motor symptoms. 
Non-motor symptoms (NMS) such as sleep disturbances, anxiety, depression, orthostatic 
hypotension and pain are however also important and common symptoms of the disease. Over 
90 % of patients across all stages of the disease suffer from NMS. 
Six patients were recruited and examined with focus on non-motor symptoms, such as pain 
and orthostatic hypotension, before and after administration of a standard dose of levodopa 
(100 mg). A screening for depression and anxiety and a motor examination was also 
performed. 
The hypothesis of this pilot study is that levodopa has a positive short term effect on NMS in 
PD patients. The aim of this study is therefore to compare NMS, particularly pain and blood 
pressure, before and after medication with levodopa in a group of newly diagnosed PD 
patients.  
The results of this study show that pain and depression are present in patient with early PD. 
It’s not possible to draw any conclusions about the short term effect of levodopa from this 
material since the results were not cohesive and the patient group was too small.  
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1 Introduction 
1.1 Parkinson’s Disease 
Many parts of the brain are involved in the process of a planned movement. Premotor cortex, 
basal ganglia and cerebellum represent important parts of the brain involved in movement. 
Disease and damage in these parts can result in movement disorders. Basal ganglia is a 
general name for some of the nucleuses in the cerebrum. Function deficit in the basal ganglia 
results in motor and non-motor complications. The most common cause for function deficit is 
neurodegenerative disorders (1). 
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder caused by loss 
of nigrostriatal dopaminergic pathways. Dopamine is a neurotransmitter and patients with 
Parkinson’s disease will eventually develop a dopamine deficiency caused by neuron 
degeneration in substansia nigra (1).  
PD is generally characterized by bradykinesia, resting tremor, rigidity and postural instability 
and the clinical diagnosis is based on these motor symptoms. Research has consequently been 
focused on these characteristics and the following treatment regimes. 
PD is not possible to cure but the symptoms can be relieved. There are many different 
treatment regimens and all must be individualized for each patient. The main goals with 
treatment are to treat the symptoms and to stop the progress of the disease. Most symptoms in 
PD are caused by dopamine deficiency. Replacement therapy of dopamine is thus a frequently 
used treatment regime. Dopamine can’t pass the blood brain barrier so instead the patients are 
given Levodopa. Levodopa is absorbed in nigrostriatal neurons where it is transformed to 
dopamine (1). Levodopa is very effective on the motor symptoms, but the effect on non-motor 
symptoms is sparsely investigated. The short-term effect of levodopa on motor symptoms is 
well documented and has good effect but the knowledge of short term effect on NMS is 
limited and thus of great interest for future research. 
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1.2 Non-motor symptoms 
Non-motor symptoms (NMS) such as sleep disturbances, anxiety, depression, orthostatic 
hypotension and pain are however also important and common symptoms of the disease (2). 
Over 90 % of patients across all stages of the disease suffer from NMS. There are two 
instruments developed to assess NMS in PD: the Non-Motor Symptoms Questionnaire 
(NMSQuest) and the Non-Motor Symptom Scale (NMSS). Studies using the NMSS suggest 
that NMS have a direct negative effect on quality of life (3). A study using the NMSQuest has 
highlighted that several non-motor issues had not been discussed with the doctor before they 
were flagged by the NMSQuest (4). 
In a study by Chaudhuri et al it was reported that several NMS are on the top five of most 
troublesome symptoms in patients with early PD and a typical patient with PD can have up to 
12 NMS (5). It has also been stated that NMS can occur in all stages of the disease, even 
before the motor symptoms. The number of NMS correlates with the duration and severity of 
PD (6). 
1.2.1 Pain 
One of the most frequent NMS in patients with PD is pain. A recently published review 
concluded that pain is observed in approximately 30 – 50% of PD patients and is most 
certainly an under diagnosed and/or overlooked symptom (5). The knowledge of the 
pathophysiology of pain in PD patients is also limited. Ford classification of pain 
distinguishes the following categories: 1) musculoskeletal pain, 2) neuropathic pain, 3) 
dystonia related pain and 4) central pain. The musculoskeletal pain is the most common pain 
within PD patient and the prevalence ranges from 45 to 75% (7). The cause of the pain sets 
the treatment therapy and the most common cause of pain is parkisonian rigidity. When the 
pain originates from the rigidity caused by the Parkinson disease it’s called secondary pain. 
When the pain is secondary to the disease the treatment is directed towards the disease and 
thereby indirectly the pain. Dopaminergic treatment such as levodopa is known to have good 
effect on motor symptoms and therefore effect on pain can be expected.  
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1.2.2 Orthostatic hypotension 
Orthostatic hypotension is also a frequent finding in patients with Parkinson's disease but its 
diagnosis remains uncertain since it is difficult to distinguish between the role of the disease 
and that of medication (8). Antiparkinsonian medication may cause autonomic dysfunction 
when levodopa is transformed to dopamine, which regulates the blood pressure through 
vasodilation.  A recent metaanalysis has shown that the prevalence of orthostatic hypotension 
in PD is about 30% (9).  
1.2.3 Depression 
The prevalence of depression amongst PD patient varies between 20 and 50% and is 
frequently associated with greater disability, rapid progression of motor symptoms and 
increased mortality (10). Depression is one of the NMS that has largest impact on quality of 
life and is often present before any motor symptoms (3). SSRI, tricyclic antidepressant and 
dopamine agonists have demonstrated antidepressant effect on depressed patients with PD 
(10).  
1.3 Scales and instruments 
The scales most frequently used in making the diagnosis of PD based on the motor symptoms 
are the Hoehn and Yahr scale (H&Y), the Schwab & England scale and the Unified 
Parkinson’s Disease Rating Scale (UPDRS). The UPDRS is the most commonly used and 
validated to document the disease and the response to medication. UDRS is a four tiered scale 
that emphasizes on motor measurements (11). In this study the UPDRS part 3 was chosen to 
measure the motor symptoms due to its validity and frequent use. 
Pain can be measured in many ways, the most common are the Visual Analogue Scale (VAS), 
Numeric Rating Scale (NRS), Verbal Rating Scale (VRS) and Faces and Pain Scale- Revised 
(FPS-R). VAS consists of a horizontal line, 100 mm in length. The end points of the VAS is 
“No pain” and “Worst imaginable pain”. The NRS is 11- point scale from 0 through 10; 0 
representing “No pain” and 10 representing “Worst imaginable pain”. The VRS is a 5- point 
scaled consisting of five phrases (no pain, mild pain, moderate pain, intense pain and 
maximum pain) that describe the pain intensity. FRS-R is 6- point scale with 6 different faces 
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that represent different stages of pain. Each illustration represents a numeric score (0, 2, 4, 6, 
8, and 10) (12). 
1.4 Aim and hypothesis 
The hypothesis of this pilot study is that levodopa has a positive short term effect on NMS in 
PD patients. The aim of this study is therefore to compare NMS, particularly pain and blood 
pressure, before and after medication with levodopa in a group of newly diagnosed PD 
patients. Degree of depression is also examined and a standard motor function test will be 
performed.  
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2 Subjects and Methods 
2.1 Patients and study design 
Six patients from the Akershus sykehus, Oslo, Norway were recruited to the study. The 
inclusion criteria were patients who had been diagnosed with Parkinson’s disease during the 
last 5 years with no previously antiparkinsonian medication. Patients with cognitive decline 
and patients who could not communicate due to other illness were excluded.  No age or 
gender limits were set. The patients were recruited when arriving for a levodopa test. 
2.2 Examination 
The patients were examined with focus on non- motor symptoms before (T0) and after (T1) 
administration of a standard dose of levodopa (100 mg). At T0 blood pressure was measured 
manually and the patients assessed perceived pain intensity and completed a questionnaire 
about anxiety and depression. The T1-examination was performed 90 minutes after levodopa 
administration and then blood pressure and pain was assessed once again. A standard motor 
examination was also carried out before and after medication. 
2.3 Outcome measures 
Blood pressure was assessed in mmHg (manual measure). Orthostatic hypotension is defined 
as a systolic or diastolic blood pressure fall of ≥ 20 mm Hg and ≥10 mmHg respectively, first 
pressure is measured lying down and the second either standing or head- up tilt to at least 60° 
within 3 min (9).   
Pain intensity was measured on a visual analog scale (VAS) which is considered to be a valid 
instrument for pain assessments (7).  
 The scale is validated to be used in both chronic and experimental pain (13). Most important, 
the VAS scale was chosen to avoid memory bias. The question asked was: 
 How much pain do you suffer from in this moment? 
No pain      Worst imaginable 
smärta 
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Hospital anxiety and depression scale (HADS) is a validated instrument used to screen for 
depression and anxiety and is the most commonly used in at Akershus Sykehus (14). The 
scale contains 7 questions about anxiety and 7 about depression. (Table 1) 
UPDRS part 3 was chosen for assessment of motor symptoms before and after medication. 
The UPDRS is used worldwide and is validated to document the disease and the response to 
medication (11). The scale included 13 domains typical for PD (see Table 2) and each 
question was graded on a 5 point scale. 
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Table 1. HADS questionnaire where A concerns anxiety and D concerns depression. 
A I feel tense or wound up: 
Most of the time -3  
A lot of the time- 2 
From time to time- 1 
Not at all – 0 
 
D I feel as if I am slowed down: 
Nearly all the time- 3 
Very often- 2 
Sometimes- 1 
Not at all- 0 
 
D I still enjoy the things I 
used to enjoy: 
Definitely as much- 0 
Not quite as much- 1 
Only a little- 2 
Hardly at all- 3 
 
A I get a sort of frightening feeling 
like butterflies in the stomach: 
Not at all- 0 
Occasionally- 1 
Quite often- 2 
Very often- 3 
A I get a sort of frightened 
feeling as if something 
awful is about to happen: 
Very definitely and quite badly-3 
Yes, but not too badly- 2 
A little but it doesn’t worry me- 1 
Not at all- 0  
 
D I have lost interest in my 
appearance: 
Definitely- 3 
I don’t as much care as much as I should- 2 
I may not take quite as much care- 1 
I take just as much care- 0 
 
D I can laugh and see the 
funny side of things: 
As much as I always could- 0 
Not quite so much now- 1 
Definitely not so much now- 2 
Not at all- 3 
 
A I feel restless as I have to be on 
the move: 
Very much indeed- 3 
Quite a lot- 2 
Not very much- 1 
Not at all- 0 
A Worrying thoughts go 
through my mind: 
A great deal of the time- 3 
A lot of the time- 2 
From time to time, but not often- 1 
Only occasionally- 0 
 
D I look forward with enjoyment to 
things: 
As much as I ever did- 0 
Rather less than I used to- 1 
Definitely less than I used to- 2 
Hardly at all- 3 
D I feel cheerful: 
Not at all- 3 
Not often- 2 
Sometimes- 1 
Most of the time- 0 
 
A I get sudden feelings of panic: 
Very often indeed- 3 
Quite often- 2 
Not very often- 1 
Not at all- 0 
A I can sit at ease and feel 
relaxed: 
Definitely- 0 
Usually- 1 
Not often- 2 
Not at all- 3 
 
D I can enjoy a good book or radio/ 
TV program: 
Often- 0 
Sometimes- 1 
Not often- 2 
Very seldom- 3 
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Table 2. Unified Parkinson’s disease Rating Scale, UPDRS part 3. 
Motor examination 0 1 2 3 4 
Speech      
Facial Expression      
Tremor at rest      
Head      
Right arm      
Left arm      
Right leg      
Left leg      
Action or postural tremor of hands      
Right      
Left      
Rigidity      
Neck      
Right arm      
Left arm      
Right leg      
Left leg      
Finger taps      
Right      
Left      
Hand movements      
Right      
Left      
Rapid alternating movements of hands      
Right      
Left      
Leg agility      
Right      
Left      
Arising from chair      
Posture      
Gait      
Postural stability      
Body bradykinesia and hypokinesia       
 
Each domain is scored from 0-4 by using a verbal rating scale. Maximum score is 56. 
Example of the grading for assessing rigidity: 
0= Absent 
1= Slight or detectable only when activated by mirror or other movements. 
2= Mild to moderate 
3= Marked, but full range of motion easily achieved. 
4= Severe, range of motion achieved with difficulty. 
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2.4 Ethics 
The Regional Committee for Medical and Health Research Ethics (REK), section South- East 
Norway granted exemption from ethical approval as the project was evaluated as a quality 
project (5/3-2012) Ref IRB 0000 1870. The Data Inspectorate Officer at Akershus sykehus 
Oslo Norway approved the study protocol (27/2-2012). A consent form was signed by each 
patient.   
2.5 Statistics 
The results of this pilot study will presented with descriptive statistics. Mean values were 
assessed for age and differences between T0 and T. 
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3 Results 
3.1 Patients 
Six patients, four women and two men were enrolled in this pilot-study. Gender, age and 
number of years with PD are presented in Table 3.  
Table 3. General data of the patients 
 Gender Age (years) Years with 
PD diagnosis 
Patient 1 F 76 5 
Patient 2 F 71 3 
Patient 3 M 75 4 
Patient 4 F 68 4 
Patient 5 F 65 5 
Patient 6 M 75 2 
Mean 
value 
 71,6 3,8 
 
3.2 Results of questionnaires and examination  
Table 4. Summary of HADS scores 
 Sum A Sum D Sum A+D 
Patient 1 6 7 13 
Patient 2 7 10 17 
Patient 3 9 9 18 
Patient 4 9 12 21 
Patient 5 4 10 14 
Patient 6 0 1 1 
Mean 
value 
5,8 8,1 14 
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Table 5. Blood pressure measurements before and after levodopa.  
 T0  T0 diff T1  T1 diff 
Patient 1 160/85 155/85 -5/0 150/80 150/80 0/0 
Patient 2  130/70 120/70 -10/0 125/70 120/65 -5/-5 
Patient 3 140/80 115/65 -25/-15 130/80 115/70 -15/-10 
Patient 4 115/65 115/60 0/-5 120/65 115/65 -5/0 
Patient 5 125/70 125/65 0/-5 120/65 120/60 0/-5 
Patient 6 130/85 130/80 0/-5 125/80 125/80 0/0 
 
Table 6. VAS of pain results before (T0) and after (T1) Levodopa. 
 T0 T1 
Patient 1 41 38 
Patient 2 0 0 
Patient 3 5 3 
Patient 4 19 16 
Patient 5 12 21 
Patient 6 0 0 
Mean value 12,8 13 
 
Table 7. Sum of UPDRS part 3 before (T0) and after (T1) Levodopa. 
 Sum T0 Sum T1 
Patient 1 30 23 
Patient 2 27 24 
Patient 3 15 10 
Patient 4 28 23 
Patient 5 22 20 
Patient 6 18 18 
Mean value 23,3 19,7 
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4 Discussion 
4.1 Method discussion 
4.1.1 Population 
The number of patients is too small for drawing any conclusions. It was difficult to enroll 
enough patients to this pilot study since the levodopa test seldom is used. Often patient are 
started on levodopa without being tested first. 
The patient group that was examined in this pilot study has recently been diagnosed with PD. 
The mean value of the patients’ age was 71, 6 years and the mean value for numbers of years 
with PD was 3, 8 years.  
4.1.2 Instruments 
The problem with many of the instruments is that the patients may remember what they 
answered on the questions. In contrast to many other pain scales the VAS is a valid 
instrument to use multiple times in a short time perspective. This was an important factor 
involved when choosing the VAS scale for this study.  
HADS is a validated screening instrument for anxiety and depression. There are several other 
questionnaires that could have been used but HADS was chosen due to its validity and the 
fact that it is commonly used at Akershus Sykehus. It’s validated for screening and not for 
multiple uses during a short period of time. That’s why the screening was performed once and 
not twice as with the other instruments. It might had been a possibility to try to use a VAS 
scale to determine short time effect of levodopa on depression. 
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4.2 Result discussion 
4.2.1 Motor function test 
A motor function test was done before and after medication. The test was done as an indicator 
of whether the patients’ PD diagnosis is correct. Levodopa will probably have a positive 
effect on the motor function if the PD diagnosis is correct. It is therefore of value to know the 
motor function test’s response to medication when testing the non-motor symptoms. A lack of 
positive response to medication in the motor function test could indicate the presence of 
another form of movement disease that doesn’t respond to levodopa. This doesn’t mean that 
all patients that don’t respond to levodopa have another disorder than PD. 
The results of the UPDRS 3 demonstrate that all patients except one had a positive effect of 
levodopa on the motor symptoms, lowering the sum of the UPDRS 3 after medication. The 
one patient (patient 6) that didn’t have any effect of Levodopa didn’t have any non-motor 
symptoms to measure the effect on either. It’ would have been interesting to screen this 
patient for non-motor symptoms with the NMSQuest or the NMSS to see whether this patient 
had any NMS.     
4.2.2 Pain 
The level of pain varied between the patients. Three out of six patients had a slight reduction 
in pain according to the VAS assessment. Two patients experienced no pain, neither before 
nor after medication and one patient experienced more pain after medication. It is impossible 
to say anything about a trend here since the results differ so much within the group of 
patients. Some patients did recognize an improvement of pain after medication so it is 
possible that there is an effect. 
The mean value of pain before medication was 12, 8 and after it was 13. Although most 
patients that experienced pain before medication thought the pain was better after medication, 
the mean value tells us different. This indicates again that the number of patients in this study 
is too low.   
The most common cause of pain in patients with PD is the secondary pain to parkisonian 
rigidity. Since the patients in this pilot study are relatively recent diagnosed their symptoms 
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are not very severe. This might be one of the reasons why the amount of pain in this group is 
not very high. The patient with the highest UPDRS score also scored highest on the pain 
score.  
4.2.3 Depression and anxiety 
The screening of depression and anxiety with the HADS questionnaire showed that all 
patients had some degree of depression and anxiety except one patient (patient 6). This patient 
didn’t have any effect of Levodopa on either of the tests. Neither did patient 6 have any of the 
NMS asked about in this study. 
 Depression is a known and frequent NMS of Parkinson’s disease. As described earlier in the 
literature we can conclude that depression and anxiety is present in early Parkinson’s disease.  
 
4.2.4 Orthostatic hypotension 
The results of the blood pressure measurements indicate that one of six patients (patient 
number 3) had orthostatic hypotension before treatment with levodopa. Orthostatic 
hypotension is defined as a fall in systolic blood pressure of ≥ 20 mm Hg or in diastolic blood 
pressure ≥10 mmHg on either standing or head- up tilt to at least 60° within 3 min. After 
medication patient number 3, did not by definition have orthostatic hypotension. 
 When comparing the T0 and T1 results of the blood pressure measurements five of six 
patients have higher blood pressure before medication than after. Many patients are nervous 
when coming to the hospital or meeting a doctor. If this is a true result or an effect of stress is 
difficult to distinguish. It might also be a side effect of the medication that causes the fall in 
blood pressure, however this should be prevented since levodopa is prepared so it is not 
transformed to dopamine before reaching the neurons in the brain.  
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4.3 Conclusion 
What can be said about the results of this study is that pain and depression are present in 
patient with early PD. There might be a trend that patients with pain felt an improvement of 
the symptoms after levodopa. It’s not possible to say anything about the short term effect of 
levodopa on NMS from this material since the patient group is too small.  
The conclusion from this study that pain and depression are present in early PD is supported 
by the literature.  
 
For future research it would be beneficial to have a larger population and test more NMS 
before and after administration of levodopa. If possible, try the instruments on a group with a 
more severe PD too. As described in the literature the number of NMS correlates with 
severity and duration of the disease and it might be easier to see an effect if the patient group 
had more symptoms to measure.  
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